Product Description: MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
Applications: COVID-19-immunoregulation
Formula: C25H29N3O3
References: [1]Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcin/[2]Orie NN, et al. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7/[3]Kuwano K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses
CAS Number: 475085-57-5
Molecular Weight: 419.52
Compound Purity: 99.91
Research Area: Cardiovascular Disease; Endocrinology
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Prostaglandin Receptor
Deutsch
English
